Index

Note: page numbers in italics refer to figures, those in bold refer to tables and boxes.

Aboriginal women, cervical smear uptake 161
acetone packs 201–2
acupuncture, chemotherapy nausea and vomiting control 112
acute radiation enteritis (ARE) 85
adenocarcinoma of the cervix 4, 40–4, 45
combination chemotherapy 43
conisation 43
diagnosis 40–1
diethylstilbestrol exposure 43–4
fertility preservation 42, 43
Glandular lesion classification 41, 42
invasive 43
metastases 43
microinvasive 43
natural history 41, 42
oestrogen association 145
ovarian preservation 142
prognosis 42
risk factors 41
in situ 42–3
stages 42–3
treatment 42, 43
tumour size 42
adenosquamous carcinoma of cervix 43
adolescence 129
HPV positive 165
HPV vaccination 212, 215
developing countries 219
male vaccination 215–16
sexual activity 212
adolescents
cervical screening 157–8

HPV vaccination decision making 212–13
African American women, cervical screening uptake 161–2
AIDS-defining illness 15, 16
Alliance for Cervical Cancer Prevention (ACCP) 174–5
Alzheimer’s disease 146
anaemia, radiotherapy 80–1
anal cancer
HPV infection 16
men who have sex with men 216
anal intra-epithelial neoplasia (AIN) 216
analgesia
advanced disease 198, 199
low dose brachytherapy 78, 79
anorexia, radiotherapy-induced 95
antibiotics
neutropenia with chemotherapy 108
prophylactic in lymphoedema 64
antidepressants 148, 199
antiemetic agents 109–10, 111
antihistamines 111
antipsychotic drugs 111
anxiety
cervical smear positive result 164
children 127–8
colposcopy 33, 34, 39, 40, 164
post-hysterectomy 57, 58
psychological effects of cervical cancer 118, 120
Index

relationship factors 121–2
sexual function impairment 123
survivorship 193
apoptosis, suppression 14
arousal, sexual 123
assisted reproductive technology (ART) 138–40
atypical squamous cells-high grade (ASC-H) 5, 6
atypical squamous cells-unspecified (ASC-US) 5, 6, 7, 31
atypical squamous cells of undetermined significance (ASCUS) 5, 6
audit, cervical screening 153, 155
Australia
cervical screening 167–8
cervical smear uptake 161
statistics for cervical screening 168
vaccination programmes 218
Australian Cervical Screening Organisation 167
Australian Modified Bethesda cervical cytology staging system 6, 7
bacterial infection 202
benzodiazepines 111
benzopyrone 65
Bethesda System (TBS) 5, 6, 7
Australian modified 6, 7
biopsy 32
see also cone biopsy
bisphosphonates 148
black cohosh 148
bladder
menopausal symptoms 143, 144
oestrogen receptors 143
radiotherapy-induced complications 89, 91–2
radiotherapy-induced fistula 76
sphincter tone 143
trauma from hysterectomy 56
blame, psychological effects of cervical cancer 118, 165
bleeding 201–2
bleomycin 105
blood transfusion, haemoglobin levels for radiotherapy 80, 81
body image 122–3
altered 124
loss 185
survivorship 193
bone marrow suppression with chemotherapy 107–8
bone mineral density 145
bowel dysfunction
chronic radiation enteritis 93
post-hysterectomy 57
radiotherapy-induced bowel perforation 93
radiotherapy-induced bowel ulceration 93
brachytherapy
exploration under anaesthetic 78
high dose 78
intra-cavity 76, 77–8
planning 78–80
low dose 77, 78
patient experience 79
prescription dose 79–80
BRCA 1 and 2 gene mutations 141
breast cancer 147
BSCC cervical cytology staging system 6
calcium channel blockers 65
Canada
cervical screening uptake 162
therapeutic vaccines 220
cancer, attitudes in developing countries 179
cancer support groups 130
cancer-associated organisations 58
carboplatin 105
emetic potential 108
carcinoma in situ (CIS) 8, 13
dysplastic continuum 13
National Women's Hospital (New Zealand) experiment 14
cardiovascular disease 144, 146
care services, support 194
caregivers, distress 193
Cervarix® 210
cervical cancer
advanced 197
asymptomatic 17
early stage 50, 51–2
invasive 7
locally advanced 50, 66
micro-invasive 50, 51
mortality rate 2
non-invasive 50, 51
progression to 15
risk factors 15–16
types 4
see also adenocarcinoma of the cervix; squamous cell carcinoma
cervical cytology
Bethesda System 5, 6
Index

grading 4, 5, 6, 7
liquid based 27–8
NHS screening programmes 7
staging systems 6
testing 26, 27
cervical histopathology, grading 7–8
cervical intra-epithelial neoplasia (CIN) 7–8
ablative techniques 36, 37, 38
excisional techniques 36–7, 38
follow-up visits 176
high grade 35–40
out-patient care of patient 37
surgical treatment 38–9
treatment side effects 38
cervical screening 2, 16–17, 153–69
access problems 160
adolescents 157–8
audit 155
consent 162–3
criteria 153, 154
developing countries 173–81
early disease detection 154
errors 153, 155
false positives/negatives 155, 156–8
human papilloma virus 156
information 162–4
instigation 158, 159
intervals 158, 159
laboratory standards 166
level of understanding 165
litigation 153, 155
minority groups 160–2
national guidelines 31, 154–5, 159
non-attendance 160, 179–80, 181
programmes 153, 154–5, 156
psychological sequelae 164–5
quality assurance 166
quality measures 156, 166
sensitivity 156–7, 175
specificity 156
termination 158, 159
vaccination programme impact 217–18
cervical smear 26, 27
abnormal 29, 30
actions 30
conventional 27–8
false negatives 27
national guidelines 31, 154–5
positive result 164
sensitivity 27
cervical stenosis, CIN treatment side effects 38
cervicography, developing countries 176–7
cervicoscopy, direct visual inspection 178
cervix 2–4
anatomy 3
role in healthy women 3
size 3
chamomile 88
charcoal dressings 202
chemoradiotherapy 81–2, 102–4, 105
agents 103–4
anal cancer 216
toxicity 82
chemotherapy 102–14
adenocarcinoma of the cervix 43
advanced disease 104–6
intra-arterial 107
nausea 108, 109
management 109–10, 111, 112
mechanism 109
risk factors 110
neoadjuvant 106–7
followed by radical surgery 137
ovarian ablation 141
ovarian failure 142
radiosensitising 102–4, 105
agents 103–4
recurrent disease 104–6
toxicity 104, 107–9, 110
vomiting 108, 109
management 109–10, 111, 112
mechanism 109
risk factors 110
children
developing countries 185, 186
talking to 127–8, 129
circumcision, male 21
cisplatin 103–4, 105
emetic potential 108
neoadjuvant therapy 137, 138
during pregnancy 138
toxicity 113
clinical target volume (CTV) 78
clonidine 199
coagulopathy 202
cognition impairment
post-menopausal 144, 146
risk of advanced stage cancer 195
survivorship 193
cold coagulation, cervical intra-epithelial neoplasia 36
colorectal cancer 146
colposcopy 7, 29
see and treat 39–40
anxiety 33, 34, 39, 40, 164
comprehensive examination 32
diagnostic 33–4
indications for 31, 32
limitations 32–3
national guidelines 31
non-attendance for treatment/follow-up 39, 40
nurse role 34, 35
nursing care of patient 33–4
one stop clinics 40
referrals 29
sensitivity 32–3
technique 31–2
training 33
uptake in developing countries 176
waiting times for results 34
communication
cervical smears in minority groups 160, 161
relationship difficulties 121
complex decongestive therapy (CDP) 63–5
efficacy 64–5
compression bandaging/hosiery 64
computed tomography (CT)
external beam radiotherapy planning 78
intra-cavity brachytherapy planning 79
staging 18, 20
condoms, HPV prevention 13
condylomata acuminata 211
cone biopsy 29
cold knife 36, 38–9, 41, 50
indications 39
fertility-preserving 136–7
laser 36
micro-invasive disease 50
pregnancy 45
cone dissection with pelvic lymph node dissection 52
consent, cervical screening 162–3
constipation, post-hysterectomy 57
coping with cervical cancer 120
avoidance 128
denial 128
style 194
counselling, fertility 137
cranberry juice 89
cryotherapy 182, 211
cyclizine 111
cystitis
chronic radiation 91–2
radiation-induced 89
cystoscopy 17
cytotoxic agents 211
defaecatory urge loss, post-hysterectomy 57
dementia, post-menopausal 144, 146
deodourisers 202
depression
post-hysterectomy 57
psychological effects of cervical cancer 118, 120
sexual function impairment 123
survivorship 193
dermatitis, radiation-induced 86–9
dressings 88–9
interventions 87
skin hygiene 87–8
topical products 88
desire, sexual 123
developing countries 173–89
adolescent vaccination 219
cancer associations/stigma 179
cervical cancer incidence 173, 186
cervical screening 173–81
acceptability 176
costs 176, 179, 182
follow-up visits 176, 181
frequency 175
implementation 174–6
implementation difficulties 175–80
infrastructure requirement 176
lack in Uganda 187
non-attendance 179–80, 181
outreach activities 181
screen and treat 178
staff requirement 176
test problems 175–8
time to obtain results 176
uptake improvement 180–1
uptake problems 175, 179–80
cervicography 176–7
colposcopy uptake 176
cryotherapy 182
economic restrictions 179
female circumcision 187–8
genital mutilation 187–8
HIV incidence 187
HPV DNA testing 177
invasive disease management 182–3
loop electrosurgical excision procedure 182
medical personnel 187
palliative care 183–4, 184–6, 187
political instability 187
pre-invasive disease management 181–2
preventive medicine lack of understanding 179
radiotherapy 183
staging systems 183
stigma of cervical cancer 179
surgery 183
treatment 181–4, 184–6
vaccines for cervical cancer 218–19
visual inspection techniques 177–8
war 187
dexamethasone 110, 111
diagnosis
cervical screening 180
fertility issues 135
human papilloma virus 165
phase 126
psychological effects 196
stage at 20
talking to children 127–8
diagnostic investigations 17–18, 19, 20
diarrhoea, radiation-induced 85–6, 95, 96
diet, acute radiation enteritis 86
diethylstilbestrol exposure, adenocarcinoma of the cervix 43–4
direct visual inspection (DVI) cervicoscopy 178
discharge, malodorous 184, 185, 186, 201, 202
distress 193
diuretics, lymphoedema management 65
don quai 148
douching 202
dressings
lumphorrhoea 203
radiation-induced dermatitis 88–9
drugs, pharmacological
lymphoedema management 65
radiation cystitis 92
radiation-induced diarrhoea 86
dyskaryosis 4, 7, 8
dyspareunia 144
sexual function impairment 123, 143
dysplasia 4, 4
carcinoma in situ 13
CIN system 8
malignant progression 14–16
progression 13–14
risk factors in persistence/progression 14–16
early stage disease 50
surgical management 51–2
economics of cervical screening in developing countries 176, 179, 182
ECTP cervical cytology staging system 6
education programmes
HPV prevention 12
lymphoedema 65–6
radical hysterectomy 59
sexual health 126
vaccines 214
embryo cryopreservation 138–9
emotional adjustment
fertility conservation 136
relationship factors 121
emotional distress, maladaptive strategies 120
endocervical curettage 33
adenocarcinoma diagnosis 41
endocervix 3
endometrial cancer 146
enteritis
acute radiation 85–6
chronic radiation 93–4, 95
epithelium 3
erythropoietin, haemoglobin levels for radiotherapy 81
evidence based medicine, cervical screening programmes 156
exercise, lymphoedema 64
exocervix 3
external beam radiotherapy (EBRT) 76
planning 78
family
developing countries 185, 186
primary care 185–6, 187
distress 193
impact 127–8, 129, 194
support 127
survivorship 193
fatigue
interference with role functioning 121
management 85
menopausal symptoms 144
radiotherapy-induced 84–5, 95
survivorship 193
fear
cervical screening in developing countries 180
of dying 118
female circumcision 187–8
femininity 122, 123
fertility loss 136
fertility 135–42
counselling 137
HPV effects 165
loss 136
survivorship 193
fertility preservation
adenocarcinoma of the cervix 42, 43
assisted reproductive technology 138–40
neoadjuvant chemotherapy 137
radical trachelectomy 52, 137
surgical techniques 136–8
surrogacy 140
see also ovarian transposition
FIGO see International Federation of Gynecology and Obstetrics (FIGO) staging
fistula 200–1
malodorous discharge 202
flaxseed 148
fluoxetine 148
formalin
intravesical instillation 92
packs 201–2
fractures, osteoporotic 145
5-FU 104, 105
emetic potential 108
gabapentin 148, 199
Gardasil® 210
licensing 218
gemcitabine 105
emetic potential 108
genital fistulas 200–1
genital mutilation 187–8
genital system, hysterectomy effects 54–6
genital warts 211
gentian violet 88, 89
ginger, chemotherapy nausea and vomiting control 112
Global Alliance for Vaccines and Immunization (GAVI) 218
D-glucosamine 92
 glutamine, acute radiation enteritis 86
gross tumour volume (GTV) 78
guided imagery, chemotherapy nausea and vomiting control 112
guilt, psychological effects of cervical cancer 118
gut wall, chronic radiation enteritis 93
haemoglobin levels during radiotherapy 80–1
haemorrhage
CIN treatment side effects 38, 39
resection 39
haemostasis 201
haloperidol 111
health belief model 212
health experiences, prior in cervical screening in developing countries 180
health professionals, HPV vaccination 214–15
health related quality of life, radiotherapy 95, 96
hereditary non-polyposis colon cancer (HNPCC) gene mutation 141
high grade squamous intraepithelial lesions (HSIL) 5, 6, 7, 8
colposcopy referral 29
HPV infection 13
regression 13
highly active antiretroviral therapy (HAART) 15, 16
HIV infection
anal cancer risk 216
developing countries 187
HPV association 12
progression 15, 16, 187
prophylaxis 219
vaccines 219
Uganda 187
HNPCC gene mutation 141
hormone therapy 145–6
administration 147–8
alternatives 148
benefits 145–6
risks 146–7
types 147
hot flushes 143, 144
hormone therapy benefits 145
5-HT_3 antagonists 110, 111
human papilloma virus (HPV) 8–16
age 11
anal cancer 216
cervical screening 156
diagnosis 165
DNA 8
DNA testing in developing countries 177
early proteins 9, 220
economic implications 10
genome 9
glandular dysplasia 41–2
high risk 10
immune status 15, 16
incidence 11–12
infection progression 13–14
information needs 165
invasion mechanism 9
late proteins 9
level of understanding 165
low risk 10
mechanism of infection 9
mutation risk 217
natural history of infection 13
oncogenesis 9, 15
oral contraceptive use 12, 16
parity 16
persistent 13
public ignorance 212
replication mechanism 9
risk factors 11–12
sexual partners 12
smoking risk 15–16
strains 10
structure 9
subtypes 10
high risk 31
symptoms 11
testing 159
low grade abnormalities 31
transmission prevention 12–13
type 16 15, 42
vaccine 210, 217
type 18 15, 42
vaccine 210, 217
vaccines/vaccination 208–20
decision making 212–15
men who have sex with men 216
of population 210, 212
prophylactic 209–10, 212–19
therapeutic 219–20
hydrocolloid dressings 89
hydrogel dressings 88, 89
hydroxyurea 104
hyperbaric oxygen 92
hyperkeratosis 203
hysterectomy 53
adenocarcinoma of the cervix 43
with bilateral oophorectomy 141
bladder trauma 56
bowel dysfunction 57
CIN treatment 39
complications 53–7
eyear stage disease 52
genital system effects 54–6
invasive cancer treatment 39
lymphocele formation 60
nerve sparing approaches 54
ovarian preservation 141
post-operative care 58–9
post-operative morbidity 54–7
post-operative pain 59
post-operative radiotherapy 54
pre-operative preparation 57–8
radical 53, 54
following pregnancy 138
nursing issues 57–9
reproductive function 54
subtotal 53
surgical approaches 53
total 53
types 53
urinary dysfunction 56–7
urinary retention 56, 58
Hystersisters 128, 130
ifosfamide 105
emetic potential 108
immune status
disease progression 15
smoking 16
immunosuppression
HPV association 12
vaccine effectiveness 219
incidence of cervical cancer 1–2
developing countries 173, 186
indigenous communities 161
infection
CIN treatment side effects 38
lymphoedema 62
inflammation, lymphoedema 62
information for patients
cervical screening 162–4
colposcopy 33–4
lymphoedema 66
psychological morbidity reduction 126
radical hysterectomy 59
radiotherapy 83
translation issues 164
informed consent, cervical screening
162–3
insomnia, menopausal symptoms 144, 145
intermittent self-catheterisation 58–9
International Federation of Gynecology
and Obstetrics (FIGO) staging 18,
19, 20
developing countries 183
Internet
  information for patients on hysterectomy 59
  support groups 130
  intra-cavity brachytherapy (ICBT) 76, 77–8
  implant insertion 79
  planning 78–80
  prescription dose 79–80
  intravenous pyelogram 18
  intravenous urogram 18
  irinotecan 105
  emetic potential 108

Jo’s Trust 128, 130
ketamine 199
koilocytosis 5

Large Loop Excision of the Transformation Zone (LLETZ) 36–7
  indications for use 39
  side effects 38
laser ablation
  cervical intra-epithelial neoplasia 36
  genital warts 211
  side effects 39
laser conisation 36
  side effects 39
learning difficulties, women with 162
lesbian women, risk of advanced stage cancer 195
libido 143, 144
  see also sexual function
lidocaine 199
life expectancy, vaccination impact 210
liquid based cytology (LBC) 27–8
litigation, cervical screening 153, 155
loop electrosurgical excision procedure (LEEP) 182, 211
lorazepam 111
low grade squamous intraepithelial lesions (LSIL) 5, 6, 7, 8
  high grade CIN 31
  HPV infection 13
  intervention 31
lower limb lymphoedema 60–6
  palliative care 202–3
lower limb oedema, radiotherapy-induced 76
lumbosacral plexopathy 198–9
lymph nodes 59–60
  biopsy 60
  dissection 59–60
  regional 20
  sentinel mapping 60
lymph vascular space invasion (LVSI) 21
lymphatic drainage, manual 63
lymphatic system 59–60
lymphocele 60
lymphoedema
  characteristic features 61
  decongestion 63–5
  diagnosis 62
  education 65–6
  grading 62–3
  incidence 61–2
  lower limb 60–6
  management 63–6
  palliative care 202–3
  prevention 65–6
  primary 61
  risk factors 62
  symptoms 62
lymphorrhoea 203
magnetic resonance imaging (MRI) 18, 20
  intra-cavity brachytherapy planning 79
malignancy
  impact on survivors 193–4
  incurable 194
  radiotherapy-induced 94–5
maxalon 110
media coverage 212
vaccine education 214
medical personnel, developing countries 187
Melacine® 220
memory impairment, post-menopausal 144
men who have sex with men (MSM) 16
  anal cancer 216
  HPV vaccination 216
menopause 3, 4, 140–8
  chemotherapy-induced 142
  early 54, 89, 123, 141
  hormone therapy 145–6
  oestrogen depletion 143
  radiotherapy-induced 89, 141–2
  sexual function 143
  surgical induction 141
  symptoms 141–2, 144
  long-term 143–4
  management 144–5
metaplasia 3
metastases
  adenocarcinoma of the cervix 43
  adjuvant radiotherapy 75
incurable malignancy 194
ovarian 141
sites 197
methotrexate, emetic potential 108
metoclopramide 111
metronidazole 202
micro-invasive disease 50
surgical management 51
minority groups
  cervical screening 160–2, 164
  risk of advanced stage cancer 195
misconceptions, cervical screening in
devolving countries 180
mitomycin C 105
myths, cervical screening in
devolving countries 180
National Health Service Cervical Screening
Programme (NHSCSP) 27, 28, 166
cervical screening for minority groups 161
National Institute for Clinical Excellence
(NICE), liquid based cytology 28
National Women’s Hospital (New Zealand)
carcinoma in situ experiment 14
nausea
  chemotherapy-induced 108, 109
    management 109–10, 111, 112
    mechanism 109
    risk factors 110
radiotherapy-induced 95
neoplasia 4, 7
  causative factors 8–9
during pregnancy 44–5
neovagina creation in pelvic
exenteration 69
nephrostomy tubes 204
neurokinin-1 receptor antagonists 110, 111
neutrophils, bone marrow suppression with
  chemotherapy 108
NHS cervical screening programmes, abnormal cytology 7
non-invasive disease 50
surgical management 51
non-steroidal anti-inflammatory drugs (NSAIDs) 199
nurse colposcopists 34, 35
nurses
  colposcopy patient care 33–4, 35
  extended role 35
  palliative care in developing countries 185–6
psychosexual needs management 127
talking about sex 124–5

obesity 195

oestrogens 92
  adenocarcinoma of the cervix
    association 145
  bone loss prevention 145
  breast cancer risk 147
  circulating 143
  depletion at menopause 143
  endometrial cancer risk 146
  hormone therapy 146, 147
  vaginal creams/pessaries 148
oncogenesis 9
oocyte cryopreservation 139
oophorectomy, bilateral 141
opiates 198, 199
oral contraceptives 12, 16
organ transplant recipients 15
  vaccine efficacy 219
orgasm 123
  impaired 124
osteoporosis 143
  hormone therapy benefits 145
osteoradionecrosis 94
ovarian failure 123, 141
ovarian metastases 141
ovarian tissue, orthoptic transplantation/
cryopreservation 139–40
ovarian transposition
  fertility preservation 137–8, 142
  radiotherapy 89
  post-hysterectomy 54
ovaries, preservation 141, 142

p53 9, 13–14
paclitaxel 105
  emetic potential 108
pain
  CIN treatment side effects 38
  low dose brachytherapy 78, 79
  neuropathic 198, 199
  nociceptive 198, 199
  post-hysterectomy 59
  radiotherapy-induced 96
  sexual function impairment 123
  syndromes 198–9
  women in developing countries 184, 185
palliative care
  developing countries 183–4, 184–6, 187
  lower limb lymphoedema 202–3
  lymphoedema 202–3
Pap smear 4
see also cervical smear
parametrial invasion 20
parents, HPV vaccination of adolescents 213–14
parity, HPV risk 16
partners
cervical screening in developing countries 179–80, 181
impact of cervical cancer 122
support for 127
support from
lack for cervical screening 179–80, 181
perceived 194
patients
information for
cervical screening 162–4
colposcopy 33–4
psychological sequelae 126
radical hysterectomy 59
radiotherapy 83
out-patient care for CIN treatment 37
preparation for pelvic exenteration 67
pelvic examination under anaesthetic (EUA) 17
pelvic exenteration 66–7, 68, 69
neovagina creation 69
patient preparation 67
post-operative morbidity 66–7, 68, 69
pre-operative psychiatric assessment 69
psychosocial adjustment 67, 69
survival 67
pelvic fractures, radiation-induced 94
pelvic lymphadenectomy, laparoscopic 52
pentoxifylline 92
percutaneous nephrostomy tube 204
physical disabilities 195
phytoestrogens 148
platinum 105
neoadjuvant therapy 137
PLISSIT model 125
pneumatic compression therapy (PCT) 63
podophyllin/podophyllotoxin 211
political instability, developing countries 187
positron emission tomography (PET) 18
post-coital bleeding 142
sexual function impairment 123
post-traumatic stress disorder (PTSD) 193
pre-dysplastic change 4
pregnancy 3
cervical neoplasia 44–5, 138
complications following CIN treatment 38, 39
cone biopsy 45
following radical trachelectomy 52
HPV risk 16
see also fertility preservation
preventive medicine, lack of understanding in developing countries 179
primrose oil 148
prochlorperazine 111
progestogens 147
prognosis 20–1, 195–6
promethazine 111
promiscuity perception 118–19
psoas syndrome 199
psychological effects of cervical cancer 55, 117–31
coping 120, 128, 194
diagnosis 196
infertility 135
poor adjustment factors 121
quality of life 118–20
recurrence 194, 196
relationships impact 120–2, 123, 124, 194
support/support groups 128, 130
timing 119
psychological effects of cervical screening 164–5
psychosexual effects of cervical cancer 55–6
management of morbidity 126, 127
nursing management 127
puberty 3
punch biopsy 32
quality of care, cervical screening in developing countries 180, 181
quality of life
malignancy impact on survivors 193–4
pelvic exenteration 66
psychological impact 118–20
radiotherapy impact 90, 95–6
relationship factors 121
response shift 96, 120
radiation
cellular effects 76
chronic cystitis 91–2
safety 77
radiation enteritis
  acute 85–6
  chronic 93–4, 95
radical trachelectomy
  early stage disease 52
  fertility-preserving 137
radiotherapy 74–96
  adjuvant 75–6
  administration methods 76
  anaemia 80–1
  bladder complications 89
  bleeding management 201
  bowel toxicity 76, 85–6, 95–6
  clinical target volume 78
  concomitant chemotherapy 81–2, 102–4, 105
  dermatitis 86–9
  developing countries 183
  DNA damage 76
  dosage 80
  early stage disease 52
  external beam 76
    planning 78
  fatigue 84–5
  fistula risk 200
  fractionation 80
  gross tumour volume 78
  image guided 82
  intensity modulated 82
  mode of action 76
  morbidity 75–6
  neoadjuvant chemotherapy 106
  ovarian ablation 141
  ovarian function effects 141–2
  pelvic fractures 94
  planning 78–80
  post-hysterectomy 54
  quality of life impact 90, 95–6
  second malignancies 94–5
  simulation 78–80
  skin damage 86–7
  toxicity 82, 83–94
    acute 83, 84–90
    late 84, 90–4
    treatment-related 83–4
  treatment
    duration 80
    factors 80–1
    optimisation 81–2
  tumour effects 76
  vaginal stenosis 90–1
  recovery phase 126
  rectal fistula, radiotherapy-induced 76
  rectal strictures, chronic radiation enteritis 93
  rectovaginal fistula 200, 201
  recurrence/recurrent disease 50
    detection 195–6
    fear 193, 194
    management 66
    psychological factors 196
    rate 194
    following radical trachelectomy 52
    survival 196
    symptoms 196
  recurrent respiratory papillomatosis (RRP) 10, 11
  red clover 148
  refugees, risk of advanced stage cancer 195
  relationships impact of cervical cancer 120–2, 194
    sexual function impairment 123, 124
  remote communities 161
  renal failure, acute 203–4
  renal obstruction 204
  reproductive function, hysterectomy 54
  reproductive tourism 140
  retinoblastoma protein (pRb) 9, 14
  rural communities 161
  screening programmes 16–17
  selective oestrogen receptor modulators (SORMs) 148
  self-administered massage (SAM) 63
  self-esteem, sexual 124
  sentinel lymph node biopsy 60
  serotonin antagonists 109
  sex, talking about 124–5
  sexual abuse, risk of advanced stage cancer 195
  sexual activity, age at commencement 212
  sexual desire 123
  sexual function 122, 123–4
    menopause 143
    post-hysterectomy 54–6
    rebuilding sexual life 126
    scales 124
    survivorship 193
  sexual health programmes 126
  sexual intercourse
    post-treatment 124, 126
    reduced frequency 123
sexual response cycle 123, 124
sexual touching, non-penetrative intimate 12–13
sexual wellbeing, pre-morbid 124
sexuality 122–3
sigmoidoscopy 17
simple lymph drainage (SLD) 63
skin care
  hygiene in radiation-induced dermatitis 87–8, 89
  lymphoedema 64, 66
skin lesions, radiation-induced 86–9
smell, discharge 184, 185, 186, 201, 202
smoking, disease progression 15–16
social factors for cervical cancer 195
social impacts of cervical cancer 117–31, 195
  recurrence 194
  timing 119
social support 120
  perceived in survivors 194
socio-economic status, risk of advanced stage cancer 195
soybeans 148
spermicides, HPV prevention 13
squamocolumnar junction 3, 4
squamous cell carcinoma 4
cytotoxic drugs 103
during pregnancy 138
staging investigations 17–18, 19, 20
staging systems 6, 7
  developing countries 183
stasis, lymphoedema 62
stents, ureteric 204
steroids
  creams for radiation-induced dermatitis 88, 89
  pain control 199
stigma of cervical cancer 212
  developing countries 179
stoma
  femininity issues 123
  pelvic exenteration 67
stress reduction, information provision 126
stroke risk 147
sucralfate 88, 89
superoxide dismutase 92
support 120
  care services 194
  long-term 128, 130
  one-to-one 130
  perceived in survivors 194
support groups 128, 130
supra-pubic catheterisation 58–9
surgery 50–70
  chronic radiation enteritis 94
  developing countries 183
  fertility-preserving 136–8
  methods 140–1
  neoadjuvant chemotherapy 106, 107
  ovarian ablation 141
  plus adjuvant radiotherapy 75–6
  radiation cystitis 92
  versus radiotherapy 74–5
see also hysterectomy; pelvic exenteration
surrogacy 140
survivorship 192–4
Sweden, cervical screening 162, 164
symptoms of cervical cancer 17
  control in advanced disease 197
  recurrence 196
teenagers 129
tenesmus, chronic radiation enteritis 93
testosterone
  endogenous 143
  hormone therapy 147
  thromboembolism 147
tibolone 147
topotecan 105
trachelectomy see radical trachelectomy
transformation zone 3
transurethral catheterisation 58–9
trauma, lymphoedema 62
treatment
  algorithm 51
  choice 196–7
  developing countries 181–4, 184–6
  fertility issues 135–6
  phase 126
see also chemoradiotherapy; chemotherapy; radiotherapy; surgery
tricyclic antidepressants 199
tumor size 20
Uganda 184–6, 186–8
  female circumcision 187–8
  HIV prevalence 187
  medical personnel 187
  palliative care 187
  political instability 187
  resources 186
United Kingdom
- cervical screening 162–3, 165–6
- uptake 161
- vaccination programmes 218

United States
- anti-vaccination minority 214
- cervical screening uptake 161–2
- vaccination programmes 218

ureteric obstruction 203–4
ureteric stents 204
urethra
- menopausal symptoms 143, 144
- oestrogen receptors 143
- radiotherapy-induced stenosis 76

urethrovaginal fistula 200
urinary catheters 58–9
- intra-cavity brachytherapy 77

urinary dysfunction, hysterectomy 56–7
urinary incontinence
- menopause 143
- post-hysterectomy 57

urinary retention, post-hysterectomy 56, 58
urogenital epithelium 143
urogenital symptoms of menopause 143
hormone therapy benefits 145

uterus 3

vaccines for cervical cancer 208–20
- cheaper strategies 219
- clinical trials 209–10
- cross-immunity between HPV strains 217
- decision making 212–15
- developing countries 218–19
- education 214
- frequency of revaccination 216–17
- funding 218
- HIV/AIDS 219
- immunocompromised people 219
- life expectancy 210
- long-term immunity 216
- oral 219
- pharmacoeconomic models 210
- population immunisation 210, 212
- prophylactic 209–10, 212–19
- public support requirement 212
- replacement strain infection 217

screening programme impacts 217–18
- target group 215–16
- therapeutic 209, 219–20

vagina
- bacterial overgrowth 202
- dilation during radiotherapy 91
- menopausal symptoms 143, 144
- hormone therapy benefits 145
- neovagina creation in pelvic exenteration 69
- oestrogen creams/pessaries 148
- oestrogen receptors 143
- radiotherapy effects 90
- stenosis 90–1
- sexual function impairment 123
- venlafaxine 148
- venous thrombosis 147
- vescicouterine fistula 200
- vesicovaginal fistula 200
- vinca alkaloids 105
- vinorelbine, emetic potential 108
- virus-like particles 209
- visual inspection with acetic acid (VIA) 177, 178
- visual inspection with Lugol’s iodine (VILI) 177
- vitamin C 88, 89
- vitamin E supplements 148
- vomiting, chemotherapy-induced 108, 109
- management 109–10, 111, 112
- mechanism 109
- risk factors 110
- vulva, oestrogen receptors 143

war in developing countries 187
warfarin, lymphoedema management 65
websites
- hysterectomy information for patients 59
- support groups 130
- wild yam 148
work impacts of cervical cancer 121
World Health Organization (WHO)
- cervical screening goals for developing countries 174
- grading system 7
- pain ladder 198
- vaccination in developing countries 218